Home page Home page
AstraZeneca

Daxas
roflumilast

Package leaflet: Information for the patient


Daxas 250 micrograms tablets

roflumilast


imageThis medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.


Reporting of side effects

image

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the nationalreportingsystem

listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


  1. How to store Daxas


    Keep this medicine out of the sight and reach of children.


    Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.


    This medicine does not require any special storage conditions.


    Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

  2. Contents of the pack and other information


What Daxas contains

The active substance is roflumilast.


Each Daxas 250 micrograms tablet contains 250 micrograms roflumilast. The other ingredients are lactose monohydrate (see section 2 under “Daxas contains lactose”), maize starch, povidone, magnesium stearate.


What Daxas looks like and contents of the pack

Daxas 250 micrograms tablets are white to off-white, embossed with ‘D’ on one side and ‘250’ on the

other side.

Each pack contains 28 tablets.


Marketing Authorisation Holder

AstraZeneca AB

SE-151 85 Södertälje Sweden


Manufacturer

Takeda GmbH

Production site Oranienburg

Lehnitzstraße 70-98

16515 Oranienburg Germany


Corden Pharma GmbH Otto-Hahn-Str.

68723 Plankstadt Germany


image

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 11

Lietuva

UAB AstraZeneca Lietuva Tel: +370 5 2660550


България

АстраЗенека България ЕООД Тел.: +359 24455000

Luxembourg/Luxemburg AstraZeneca S.A./N.V. Tél/Tel: +32 2 370 48 11


Česká republika

AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 111

Magyarország AstraZeneca Kft. Tel.: +36 1 883 6500


Danmark AstraZeneca A/S Tlf: +45 43 66 64 62

Malta

Associated Drug Co. Ltd Tel: +356 2277 8000


Deutschland AstraZeneca GmbH Tel: +49 41 03 7080

Nederland

AstraZeneca BV

Tel: +31 79 363 2222


Eesti

AstraZeneca

Norge

AstraZeneca AS

Tel: +372 6549 600 Tlf: +47 21 00 64 00


Ελλάδα

AstraZeneca A.E.

Τηλ: +30 210 6871500

Österreich

AstraZeneca Österreich GmbH Tel: +43 1 711 31 0


España

AstraZeneca Farmacéutica Spain, S.A. Tel: +34 91 301 91 00

Polska

AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 00


France

AstraZeneca

Tél: +33 1 41 29 40 00

Portugal

AstraZeneca Produtos Farmacêuticos, Lda. Tel: +351 21 434 61 00


Hrvatska AstraZeneca d.o.o. Tel: +385 1 4628 000

România

AstraZeneca Pharma SRL Tel: +40 21 317 60 41


Ireland

AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7100

Slovenija

AstraZeneca UK Limited Tel: +386 1 51 35 600


Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika AstraZeneca AB, o.z. Tel: +421 2 5737 7777


Italia

Simesa S.p.A.

Tel: +39 02 9801 1

Suomi/Finland

AstraZeneca Oy

Puh/Tel: +358 10 23 010


Κύπρος

Αλέκτωρ Φαρµακευτική Λτδ Τηλ: +357 22490305

Sverige

AstraZeneca AB

Tel: +46 8 553 26 000


Latvija

SIA AstraZeneca Latvija Tel: +371 67377100

United Kingdom (Northern Ireland)

AstraZeneca UK Ltd Tel: +44 1582 836 836


This leaflet was last approved in